<DOC>
	<DOCNO>NCT00004468</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate long term safety efficacy orally administer calcitriol patient least 5 % body covered psoriasis . II . Evaluate long term safety efficacy topically administer calcitriol patient least 5 % body covered psoriasis . III . Compare topical calcitriol treatment oral calcitriol treatment patient .</brief_summary>
	<brief_title>Study Topical Calcitriol Oral Calcitriol Patients With Psoriasis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This part placebo-controlled ( arm I ) study . Patients either apply topical petrolatum ( Vaseline ) calcitriol ( vitamin D3 ) psoriatic lesion daily petrolatum similar lesion daily serve control ( arm I ) receive oral calcitriol nightly ( arm II ) . Arm I patient continue treatment least 2 month . At end 2 month topical treatment , one biopsy take lesion treat calcitriol , one biopsy lesion treat petrolatum alone , one biopsy skin unaffected psoriasis . Lesions also photograph prior therapy , 2-4 week therapy first two month , every 1-3 month , end treatment . Arm II patient increase dosage oral calcitriol every 2 week maximum dosage daily absence adverse effect ( high urinary calcium serum calcium level ) . Patients continue treatment least 1 month . Lesions photograph prior therapy , 2-4 week therapy , end treatment .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Psoriasis cover least 5 % body Prior/Concurrent Therapy At least 30 day since prior systemic therapy psoriasis At least 14 day since prior topical therapy psoriasis No concurrent treatment psoriasis first 24 month study No calcium supplement great 1,000 mg per day Patient Characteristics No hypercalcemia No hypercalciuria Not pregnant Effective contraception require fertile patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>dermatologic disorder</keyword>
	<keyword>psoriasis</keyword>
	<keyword>rare disease</keyword>
</DOC>